147 related articles for article (PubMed ID: 12880987)
21. Immunoliposomal fenretinide: a novel antitumoral drug for human neuroblastoma.
Raffaghello L; Pagnan G; Pastorino F; Cosimo E; Brignole C; Marimpietri D; Bogenmann E; Ponzoni M; Montaldo PG
Cancer Lett; 2003 Jul; 197(1-2):151-5. PubMed ID: 12880975
[TBL] [Abstract][Full Text] [Related]
22. Use of c-myb antisense oligonucleotides to increase the sensitivity of human colon cancer cells to cisplatin.
Funato T; Satou J; Kozawa K; Fujimaki S; Miura T; Kaku M
Oncol Rep; 2001; 8(4):807-10. PubMed ID: 11410788
[TBL] [Abstract][Full Text] [Related]
23. Biodistribution, stability, and antiviral efficacy of liposome-entrapped phosphorothioate antisense oligodeoxynucleotides in ducks for the treatment of chronic duck hepatitis B virus infection.
Soni PN; Brown D; Saffie R; Savage K; Moore D; Gregoriadis G; Dusheiko GM
Hepatology; 1998 Nov; 28(5):1402-10. PubMed ID: 9794928
[TBL] [Abstract][Full Text] [Related]
24. c-myc antisense oligodeoxyribonucleotides inhibit proliferation of non-small cell lung cancer.
Robinson LA; Smith LJ; Fontaine MP; Kay HD; Mountjoy CP; Pirruccello SJ
Ann Thorac Surg; 1995 Dec; 60(6):1583-91. PubMed ID: 8787447
[TBL] [Abstract][Full Text] [Related]
25. Enhanced accumulation of long-circulating liposomes modified with the nucleosome-specific monoclonal antibody 2C5 in various tumours in mice: gamma-imaging studies.
Elbayoumi TA; Torchilin VP
Eur J Nucl Med Mol Imaging; 2006 Oct; 33(10):1196-205. PubMed ID: 16763815
[TBL] [Abstract][Full Text] [Related]
26. Tumor vascular targeted liposomal-bortezomib minimizes side effects and increases therapeutic activity in human neuroblastoma.
Zuccari G; Milelli A; Pastorino F; Loi M; Petretto A; Parise A; Marchetti C; Minarini A; Cilli M; Emionite L; Di Paolo D; Brignole C; Piaggio F; Perri P; Tumiatti V; Pistoia V; Pagnan G; Ponzoni M
J Control Release; 2015 Aug; 211():44-52. PubMed ID: 26031842
[TBL] [Abstract][Full Text] [Related]
27. Combined targeting of perivascular and endothelial tumor cells enhances anti-tumor efficacy of liposomal chemotherapy in neuroblastoma.
Loi M; Marchiò S; Becherini P; Di Paolo D; Soster M; Curnis F; Brignole C; Pagnan G; Perri P; Caffa I; Longhi R; Nico B; Bussolino F; Gambini C; Ribatti D; Cilli M; Arap W; Pasqualini R; Allen TM; Corti A; Ponzoni M; Pastorino F
J Control Release; 2010 Jul; 145(1):66-73. PubMed ID: 20346382
[TBL] [Abstract][Full Text] [Related]
28. Effect of cisplatin and c-myb antisense phosphorothioate oligodeoxynucleotides combination on a human colon carcinoma cell line in vitro and in vivo.
Del Bufalo D; Cucco C; Leonetti C; Citro G; D'Agnano I; Benassi M; Geiser T; Zon G; Calabretta B; Zupi G
Br J Cancer; 1996 Aug; 74(3):387-93. PubMed ID: 8695353
[TBL] [Abstract][Full Text] [Related]
29. Oligonucleotide N3'-->P5' phosphoramidates as antisense agents.
Gryaznov S; Skorski T; Cucco C; Nieborowska-Skorska M; Chiu CY; Lloyd D; Chen JK; Koziolkiewicz M; Calabretta B
Nucleic Acids Res; 1996 Apr; 24(8):1508-14. PubMed ID: 8628685
[TBL] [Abstract][Full Text] [Related]
30. c-Met antisense oligodeoxynucleotides as a novel therapeutic agent for glioma: in vitro and in vivo studies of uptake, effects, and toxicity.
Chu SH; Zhang H; Ma YB; Feng DF; Zhu ZA; Yuan XH; Li ZQ
J Surg Res; 2007 Aug; 141(2):284-8. PubMed ID: 17561117
[TBL] [Abstract][Full Text] [Related]
31. A DNA uptake-stimulating protein increases the antiproliferative effect of c-myb antisense oligonucleotide on leukemic cells.
Tóth G; Schlammadinger J; Aradi J; Antal-Szalmás P; Sipka S; Balázs M; Kovács P; Fehér Z; Falus A
Cell Biol Int; 2004; 28(11):817-23. PubMed ID: 15563404
[TBL] [Abstract][Full Text] [Related]
32. A novel, long-circulating, and functional liposomal formulation of antisense oligodeoxynucleotides targeted against MDR1.
Stuart DD; Kao GY; Allen TM
Cancer Gene Ther; 2000 Mar; 7(3):466-75. PubMed ID: 10766353
[TBL] [Abstract][Full Text] [Related]
33. Targeted delivery to neuroblastoma of novel siRNA-anti-GD2-liposomes prepared by dual asymmetric centrifugation and sterol-based post-insertion method.
Adrian JE; Wolf A; Steinbach A; Rössler J; Süss R
Pharm Res; 2011 Sep; 28(9):2261-72. PubMed ID: 21594716
[TBL] [Abstract][Full Text] [Related]
34. In vitro and in vivo antitumor activity of liposomal Fenretinide targeted to human neuroblastoma.
Raffaghello L; Pagnan G; Pastorino F; Cosimo E; Brignole C; Marimpietri D; Montaldo PG; Gambini C; Allen TM; Bogenmann E; Ponzoni M
Int J Cancer; 2003 May; 104(5):559-67. PubMed ID: 12594810
[TBL] [Abstract][Full Text] [Related]
35. Liposome-mediated therapy of neuroblastoma.
Di Paolo D; Loi M; Pastorino F; Brignole C; Marimpietri D; Becherini P; Caffa I; Zorzoli A; Longhi R; Gagliani C; Tacchetti C; Corti A; Allen TM; Ponzoni M; Pagnan G
Methods Enzymol; 2009; 465():225-49. PubMed ID: 19913170
[TBL] [Abstract][Full Text] [Related]
36. Liposomal targeting of bcl-2 antisense oligonucleotides with enhanced stability into human myeloma cell lines.
Ollikainen H; Lappalainen K; Jääskeläinen I; Syrjänen S; Pulkki K
Leuk Lymphoma; 1996 Dec; 24(1-2):165-74. PubMed ID: 9049973
[TBL] [Abstract][Full Text] [Related]
37. The effect of oligonucleotides to c-myb on vascular smooth muscle cell proliferation and neointima formation after porcine coronary angioplasty.
Gunn J; Holt CM; Francis SE; Shepherd L; Grohmann M; Newman CM; Crossman DC; Cumberland DC
Circ Res; 1997 Apr; 80(4):520-31. PubMed ID: 9118483
[TBL] [Abstract][Full Text] [Related]
38. Characteristics and biodistribution of soybean sterylglucoside and polyethylene glycol-modified cationic liposomes and their complexes with antisense oligodeoxynucleotide.
Shi J; Yan WW; Qi XR; Maitani Y; Nagai T
Drug Deliv; 2005; 12(6):349-56. PubMed ID: 16253950
[TBL] [Abstract][Full Text] [Related]
39. Highly efficient cellular uptake of c-myb antisense oligonucleotides through specifically designed polymeric nanospheres.
Tondelli L; Ricca A; Laus M; Lelli M; Citro G
Nucleic Acids Res; 1998 Dec; 26(23):5425-31. PubMed ID: 9826768
[TBL] [Abstract][Full Text] [Related]
40. Targeting liposomal chemotherapy via both tumor cell-specific and tumor vasculature-specific ligands potentiates therapeutic efficacy.
Pastorino F; Brignole C; Di Paolo D; Nico B; Pezzolo A; Marimpietri D; Pagnan G; Piccardi F; Cilli M; Longhi R; Ribatti D; Corti A; Allen TM; Ponzoni M
Cancer Res; 2006 Oct; 66(20):10073-82. PubMed ID: 17047071
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
